Multiple Myeloma News
Functional Disability Predicts Mortality in Older Adults With Newly Diagnosed Multiple Myeloma
Source: Myeloma - Hematology Advisor Among older adults with multiple myeloma (MM) receiving home health services, functional disability is a predictor of early mortality, according to research published in JCO Clinical Cancer Informatics. “The care of patients with...
FDA Advisory Committee Votes in Favor of Ide-Cel for Adult Patients With Multiple Myeloma
Source: Pharmacy Times articles The decision to vote in favor of idecabtagene vicleucel comes after positive phase 3 trial results demonstrating its efficacy compared with standard regimens. Read More
Elranatamab Maintains or Improves Symptoms and Health Status of Patients With Multiple Myeloma
Source: Pharmacy Times articles This finding was evident in both examined groups and regardless of the patients' B-cell maturation antigen-directed therapy status. Read More
GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other Benefits When Combined With Bortezomib
Source: Pharmacy Times articles The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced. Read More
FDA Approves Denosumab Biosimilars Jubbonti and Wyost
Source: Myeloma - Hematology Advisor The Food and Drug Administration has approved Jubbonti® (denosumab-bbdz) and Wyost® (denosumab-bbdz), the first interchangeable biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively. Jubbonti is approved to treat...
Multiple Myeloma Awareness Month: Raising Awareness, Sharing Stories With #MyelomaActionMonth
Source: Pharmacy Times articles This initiative aims to raise worldwide awareness of the disease while trying to strengthen the connection between members of the multiple myeloma community. Read More
Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma
Source: Pharmacy Times articles Panelists provide concluding perspectives on the operationalization of bispecific antibodies for multiple myeloma. Read More
Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier
Source: Myeloma : nature.com subject feeds Post Content Read More
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group
Source: Myeloma : nature.com subject feeds Post Content Read More
Belantamab Mafodotin Regimen Indicates Safety, Improved OS in Patients Treated With Multiple Myeloma
Source: Pharmacy Times articles Despite the belantamab mafodotin regimen improving overall survival in patients with relapsed or refractory multiple myeloma, the trial is ongoing to confirm the presented results. Read More